HCM
SAGE

Harvey Capital Management’s Sage Therapeutics SAGE Stock Holding History

Harvey Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-14,630
Closed -$673K – 81
2016
Q3 		$673K Sell
14,630
-915
-6% -$37.2K 0.21% 48
2016
Q2 		$468K Sell
15,545
-1,360
-8% -$45.3K 0.23% 53
2016
Q1 		$541K Sell
16,905
-750
-4% -$26.4K 0.26% 53
2015
Q4 		$1.03M Sell
17,655
-1,850
-9% -$91.6K 0.41% 46
2015
Q3 		$825K Buy
+19,505
New +$1.2M 0.33% 48

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Harvey Capital Management's SAGE Position: Q4 2016 in Review

Harvey Capital Management sold out of Sage Therapeutics (SAGE) in Q4 2016, closing a stake of 14,630 shares — an estimated $673K sold.

Harvey Capital Management first reported a position in SAGE in Q3 2015 and held it in 5 quarters. The position peaked at $1.03M in Q4 2015. 166 funds tracked by Wall St. Rank hold SAGE as of Q4 2016.

  • Harvey Capital Management reported no remaining Sage Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Harvey Capital Management sold 14,630 Sage Therapeutics shares in Q4 2016, an estimated $673K.
  • Harvey Capital Management first reported a position in Sage Therapeutics in Q3 2015 and held it in 5 quarters.
  • Harvey Capital Management's Sage Therapeutics position peaked at $1.03M in Q4 2015.
  • 166 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2016.

Based on Harvey Capital Management's 13F filing for Q4 2016, filed 27 Jan 2017.